These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 12811512

  • 1. Population pharmacokinetics of oral busulfan in children.
    Schiltmeyer B, Klingebiel T, Schwab M, Mürdter TE, Ritter CA, Jenke A, Ehninger G, Gruhn B, Würthwein G, Boos J, Hempel G.
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
    [Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
    Trame MN, Bergstrand M, Karlsson MO, Boos J, Hempel G.
    Clin Cancer Res; 2011 Nov 01; 17(21):6867-77. PubMed ID: 21918171
    [Abstract] [Full Text] [Related]

  • 3. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study.
    Bertholle-Bonnet V, Bleyzac N, Galambrun C, Mialou V, Bertrand Y, Souillet G, Aulagner G.
    Ther Drug Monit; 2007 Apr 01; 29(2):177-84. PubMed ID: 17417071
    [Abstract] [Full Text] [Related]

  • 4. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
    Nguyen L, Leger F, Lennon S, Puozzo C.
    Cancer Chemother Pharmacol; 2006 Jan 01; 57(2):191-8. PubMed ID: 16133536
    [Abstract] [Full Text] [Related]

  • 5. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
    Blair EY, Rivory LP, Clarke SJ, McLachlan AJ.
    Br J Clin Pharmacol; 2004 Apr 01; 57(4):416-26. PubMed ID: 15025739
    [Abstract] [Full Text] [Related]

  • 6. Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation.
    Takama H, Tanaka H, Nakashima D, Ueda R, Takaue Y.
    Bone Marrow Transplant; 2006 Feb 01; 37(4):345-51. PubMed ID: 16400337
    [Abstract] [Full Text] [Related]

  • 7. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H, Mayer PR, Wajdula J, Fatenejad S.
    J Clin Pharmacol; 2004 Nov 01; 44(11):1235-43. PubMed ID: 15496641
    [Abstract] [Full Text] [Related]

  • 8. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies.
    Mougenot P, Pinguet F, Fabbro M, Culine S, Poujol S, Astre C, Bressolle F.
    Cancer Chemother Pharmacol; 2004 Jun 01; 53(6):503-12. PubMed ID: 15007638
    [Abstract] [Full Text] [Related]

  • 9. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
    Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA, Choroszy M, Danielson M, Przepiorka D, Chan KW.
    Bone Marrow Transplant; 2000 Sep 01; 26(5):463-70. PubMed ID: 11019834
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
    Schechter T, Finkelstein Y, Doyle J, Verjee Z, Moretti M, Koren G, Dupuis LL.
    Biol Blood Marrow Transplant; 2007 Mar 01; 13(3):307-14. PubMed ID: 17317584
    [Abstract] [Full Text] [Related]

  • 11. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.
    Vassal G, Michel G, Espérou H, Gentet JC, Valteau-Couanet D, Doz F, Mechinaud F, Galambrun C, Neven B, Zouabi H, Nguyen L, Puozzo C.
    Cancer Chemother Pharmacol; 2008 Jan 01; 61(1):113-23. PubMed ID: 17393167
    [Abstract] [Full Text] [Related]

  • 12. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients.
    Zwaveling J, Press RR, Bredius RG, van Derstraaten TR, den Hartigh J, Bartelink IH, Boelens JJ, Guchelaar HJ.
    Ther Drug Monit; 2008 Aug 01; 30(4):504-10. PubMed ID: 18641537
    [Abstract] [Full Text] [Related]

  • 13. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
    Staatz CE, Tett SE.
    Eur J Clin Pharmacol; 2002 Dec 01; 58(9):597-605. PubMed ID: 12483452
    [Abstract] [Full Text] [Related]

  • 14. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F, Letrent SP, Sharma A.
    Cancer Chemother Pharmacol; 2007 Nov 01; 60(6):799-809. PubMed ID: 17285315
    [Abstract] [Full Text] [Related]

  • 15. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.
    Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C.
    Bone Marrow Transplant; 2004 May 01; 33(10):979-87. PubMed ID: 15064687
    [Abstract] [Full Text] [Related]

  • 16. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE, Würthwein G, Joachim B, Boddy AV, Krischke M, Fuhr U, Thompson PA, Jörger M, Schellens JH, Hempel G.
    Cancer Chemother Pharmacol; 2013 Mar 01; 71(3):749-63. PubMed ID: 23314734
    [Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D, Mondick JT, Jayaraman B, Thompson PA, Blaney SM, Bernstein M, Bond M, Champagne M, Fossler MJ, Barrett JS.
    Cancer Chemother Pharmacol; 2009 Jan 01; 63(2):229-38. PubMed ID: 18398615
    [Abstract] [Full Text] [Related]

  • 18. Population pharmacokinetics of cisplatin in adult cancer patients.
    de Jongh FE, Gallo JM, Shen M, Verweij J, Sparreboom A.
    Cancer Chemother Pharmacol; 2004 Aug 01; 54(2):105-12. PubMed ID: 15127229
    [Abstract] [Full Text] [Related]

  • 19. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
    Zwaveling J, den Hartigh J, Lankester AC, Guchelaar HJ, Egeler RM, Bredius RG.
    Anticancer Drugs; 2006 Oct 01; 17(9):1099-105. PubMed ID: 17001185
    [Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetic model of PI-88, a heparanase inhibitor.
    Hudachek SF, Eckhardt SG, Hicks B, Gustafson DL.
    Cancer Chemother Pharmacol; 2010 Mar 01; 65(4):743-53. PubMed ID: 19633850
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.